In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...